Breast cancer followed by corpus cancer: Is there a higher risk for aggressive histologic subtypes?

Etiologic heterogeneity in endometrial cancer: Evidence from a Gyneco- logic Oncology Group trial

“…A number of previous studies have noted the development of uterine serous cancers among women with breast cancer [7,[36][37][38][39], but our results expand on these findings by showing that breast cancer predisposes to serous cancers as well as carcinosarcomas and grade 3 endometrioid tumors. Several hypotheses have been proposed for the excess of endometrial cancers among women with prior breast cancer, including similar risk profiles, radiation treatment of proximate organs, manifestations of rare inherited cancer syndromes (e.g., Li-Fraumeni and Lynch syndromes), or the result of mutations in cancer predisposing genes [40,41].…”

Uterine papillary serous cancer: A review of the literature

“…Several studies have reported an association between UPSC and breast cancer [26][27][28][29]. In the study by Growdon et al, reporting outcomes of 84 women with stage I UPSC, a second malignancy was seen in 38 patients (45%), and specifically, breast cancer was noted in 22 women (26%) [26].…”

Endometrial Intraepithelial Neoplasia

“…Definitive risk factors for type II endometrial cancer are still unclear, however. In one recent study, we found that women 55 years of age or under with a personal history of breast cancer, had an increased risk of ESC as compared with controls (Liang, Pearl et al 2010), and an earlier study by Chan et al came to comparable conclusions 2006 (Chan, Manuel et al 2006). These Type II cancers, most notably ESC, also exhibit frequent mutation and overexpression of the p53 (Sherman, Bur et al 1995;Nordstrom, Strang et al 1996) and HER2/neu (Rolitsky, Theil et al 1999) genes and proteins, respectively.…”

“…Based on epidemiologic data, Chan et al had reported an association between breast cancer and endometrial cancers with aggressive histological types (Chan, Manuel et al 2006). In 2007, a Swedish study found that 7.28% of patients undergoing genetic counseling for an increased risk of breast cancer, had family histories of both endometrial and breast cancers (von Wachenfeldt, Lindblom et al 2007).…”

“…The approach at our institute is based on our consideration of these patients to be at a significantly higher risk for the development of endometrial malignancy than their counterparts without EmGD, and that this risk is accentuated by factors such as a personal history of breast cancer or BRCA mutations (Chan, Manuel et al 2006;Liang, Pearl et al 2010). For patients without breast cancer history and/or BRCA mutations, if the diagnosis of EmGD is confirmed in a biopsy, we recommend complete dilation and curettage (D&C) for larger sampling.…”